Lyn Jones, PhD | Director
Lyn Jones completed his Ph.D. studies in synthetic organic chemistry at the University of Nottingham, before starting his post-doctorate research at The Scripps Research Institute, California in the area of chemical biology.
In 2001, he joined Pfizer (Sandwich, UK) as a medicinal chemistry team leader. In 2011, he transferred to Cambridge, MA to become Head of Rare Disease Chemistry and to lead the Chemical Biology Group, before joining Jnana Therapeutics as Vice President of Chemistry and Chemical Biology. He is currently Director of the Center for Protein Degradation at the Dana-Farber Cancer Institute. He is an author of over 100 publications, a fellow of the Royal Society of Chemistry (FRSC), the Royal Society of Biology (FRSB) and the Linnean Society (FLS), and on the editorial boards for several medicinal chemistry journals.
In 2001, he joined Pfizer (Sandwich, UK) as a medicinal chemistry team leader. In 2011, he transferred to Cambridge, MA to become Head of Rare Disease Chemistry and to lead the Chemical Biology Group, before joining Jnana Therapeutics as Vice President of Chemistry and Chemical Biology. He is currently Director of the Center for Protein Degradation at the Dana-Farber Cancer Institute. He is an author of over 100 publications, a fellow of the Royal Society of Chemistry (FRSC), the Royal Society of Biology (FRSB) and the Linnean Society (FLS), and on the editorial boards for several medicinal chemistry journals.